This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1566 entries already.
French targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
LINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply.
German-Canadian food tech specialist The Cultivated B reports that it has identified a small molecule that can replace bovine fibroblast growth factor (bFGF) in the production of cell-based meat with a stable, scalable small molecule that results in reproducible quality of sustainably cultured meat.
The new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
German BRAIN Biotech AG and the Switzerland’s PX Group will extend its partnership within the framework of the PX Urban Mining Initiative. The extension builds on previous work, which focused on providing a proof of concept for the biological recovery of gold from e-waste and other gold-containing side streams.
German API and antibody drug conjugate (ADC) CDMO Axplora Group GmbH has announced an investment of €50m in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases.
Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI) has granted US$5m to RNA formulation specialis Ethris to support studies that demonstrate spray-dried RNA vaccines remain stable at room temperature and are suitable for mucosal delivery.
Now that US President Donald Trump has loudly announced his intention to withdraw from the Paris climate targets and refocus the US economy on fossil fuel production, Europe, which is still a leader in the bioeconomy, is sensing an opportunity. A new cluster alliance of 14 production sites wants to advance the high-tech bioeconomy.
Hair loss therapeutics developer Mallia Therapeutics and Northway Biotech have partners to set up a manufacturing process of soluble CD83 protein to prevent and cure hair loss.
Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.